- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03670836
Comparison of Misoprostol Ripening Efficacy With Dilapan (COMRED)
Dilapan vs Misoprostol for Cervical Ripening [COMRED - Comparison of Misoprostol Ripening Efficacy With Dilapan]
Study Overview
Status
Intervention / Treatment
Detailed Description
In developed nations 25 % of pregnant women undergo labor induction for various indications. Likelihood of vaginal delivery depends on the degree of ripeness of cervix. Majority of women undergoing induction of labor are candidates for cervical ripening. Dilapan is an osmotic hygroscopic dilator of cervix commonly used for cervical preparation for mid trimester abortions. It has been proven safe for use for induction of Labor (IOL) at term. Misoprostol is a synthetic prostaglandin E1 analogue, widely used for cervical ripening and IOL in United States and is considered as standard of care.
This is a non-inferiority, unblinded randomized, controlled trial where 322 eligible participants undergoing IOL at >37 weeks gestation and admitted to labor and delivery unit will be enrolled and randomly assigned in a ratio 1:1 to either receive Dilapan or Misoprostol for cervical ripening.
After randomization all participants will undergo assessment as per standard of care. Participants will have either 1-5 Dilapan rods inserted into their cervix by the providers or receive 25 mcg of misoprostol orally every 2 hours to a maximum of 6 doses over 12 hours. Participants will be evaluated for artificial rupture of membranes and initiation of oxytocin for inducing uterine contraction. A diagnosis of failed IOL will be made if patient does not go into active labor within 24 hours after initiation of Oxytocin and Artificial Rupture Of Membranes (AROM). Intrapartum management will be according to institutional guidelines. All participants will be followed up and contacted by phone 2 weeks after discharge regarding their experience with the method of induction.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10034
- New York Presbyterian - Allen Hospital
-
-
Texas
-
Galveston, Texas, United States, 77555
- University of Texas
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Women undergoing labor induction with a gestation of ≥37 weeks (based on a sure last menstrual period and an ultrasound done before 22 0/7 weeks)
- Live fetus with in cephalic presentation
- Singleton pregnancy
- Able to provide informed consent for participation in the study
Exclusion Criteria:
- Contraindication for vaginal delivery
- Age less than 18 years
- Prior uterine scar from a cesarean section or myomectomy
- Patients who have HELLP syndrome or eclampsia
- Active genital herpes at the time of labor induction
- Complex medical problems that may require assistance with second stage of labor
- Bishop score ≥ 6
- Major fetal congenital anomalies (as assessed by investigator)
- Premature rupture of membranes
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Dilapan group
Patients who are randomized to receive Dilapan, will have 3-5 rods of Dilapan-S® inserted in their cervix by the supervising provider, under aseptic precautions with a speculum exam, either digitally or using a sponge forceps, as per manufacturer's recommendations.
The Bishop score at the time of eligibility assessment and number of rods inserted will be recorded.
Dilapan will be left in cervix for 12 hours.
Patients will be allowed to ambulate, shower and have light meals as long as they meet the criteria based on institutional guidelines for intermittent fetal heart monitoring.
"Nothing per vagina" including douching and no bathing is allowed.
|
Dilapan-S® is a mechanical method for cervical ripening using rods made of a patented hydrogel Aquacryl, it is marketed in form of rods of 3 and 4 mm diameter.
It is FDA approved for cervical ripening.
Other Names:
|
EXPERIMENTAL: Misoprostol group
Patients who are randomized to Misoprostol group, after the baseline assessment and a reassuring cardiotocograms (CTG) monitoring for 20 minutes to a maximum of 6 doses.
All subjects will have continuous fetal monitoring.
A dose will be held if patient is noted to have uterine tachysystole, hyperstimulation, fetal heart tracing abnormalities or 3 or more painful uterine contractions over a period of 10 minutes (indicating onset of labor).
Administration of Misoprostol will be done by the nurse assigned to the patient.
|
25mcg of Misoprostol will be administered orally every 2 hours (maximum of 6 doses) Misoprostol is a prostaglandin E1 analog approved for treatment and prevention of gastric ulcers. The use of Misoprostol appears to be safe and effective for induction of labor when used in low dose.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of women achieving vaginal delivery
Time Frame: Up to 36 hours after intervention
|
This is to measure the efficacy of either Dilapan or Misoprostol for cervical ripening
|
Up to 36 hours after intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Bishop score
Time Frame: At 12 hours after intervention
|
The Bishop Score (also known as Pelvic Score) is the most commonly used method to rate the readiness of the cervix for induction of labor.
The Bishop Score gives points to 5 measurements of the pelvic examination dilation, effacement of the cervix, station of the fetus, consistency of the cervix, and position of the cervix.
It ranges from 0 to 13.
Higher score is associated with increased likelihood of vaginal delivery.
|
At 12 hours after intervention
|
Percentage of women delivering vaginally in 24 hours after the initiation of intervention
Time Frame: Up to 24 hours after intervention
|
This is to measure the efficacy of either Dilapan or Misoprostol for cervical ripening
|
Up to 24 hours after intervention
|
Overall vaginal delivery rate
Time Frame: Approximately up to 48 hours
|
This is to measure the efficacy of either Dilapan or Misoprostol for cervical ripening
|
Approximately up to 48 hours
|
Rate of cesarean deliveries
Time Frame: Approximately up to 48 hours
|
This is to measure the efficacy of either Dilapan or Misoprostol for cervical ripening
|
Approximately up to 48 hours
|
Total length of hospital stay
Time Frame: Up to 4 days
|
This is to measure the cost-effectiveness of either Dilapan or Misoprostol for cervical ripening.
Length will be measured in number of days from hospital admission until discharge.
|
Up to 4 days
|
Percentage of women who developed chorioamnionitis
Time Frame: From delivery until two weeks after discharge (approximately up to 3 weeks)
|
This is to measure the safety of either Dilapan or Misoprostol for cervical ripening
|
From delivery until two weeks after discharge (approximately up to 3 weeks)
|
Percentage of women who developed endometritis within 14 days of intervention
Time Frame: From delivery until two weeks after discharge (approximately up to 3 weeks)
|
This is to measure the safety of either Dilapan or Misoprostol for cervical ripening
|
From delivery until two weeks after discharge (approximately up to 3 weeks)
|
Percentage of women who developed postpartum hemorrhage
Time Frame: From delivery until two weeks after discharge (approximately up to 3 weeks)
|
This is to measure the safety of either Dilapan or Misoprostol for cervical ripening, postpartum hemorrhage is defined as estimated blood loss (EBL) > 1000cc and/or drop in Hematocrit (HCT) by 10 points.
|
From delivery until two weeks after discharge (approximately up to 3 weeks)
|
Percentage of newborns with Apgar score <7 at 5 min
Time Frame: From birth until two weeks after birth
|
This is to measure the safety of either Dilapan or Misoprostol for cervical ripening by studying the effect on newborns
|
From birth until two weeks after birth
|
Percentage of newborns with cord arterial blood potential hydrogen (pH) < 7
Time Frame: From birth until two weeks after birth
|
This is to measure the safety of either Dilapan or Misoprostol for cervical ripening by studying the effect on newborns
|
From birth until two weeks after birth
|
Percentage of newborns with neonatal intensive care unit (NICU) admission within 14 days after study intervention
Time Frame: From birth until two weeks after birth
|
This is to measure the safety of either Dilapan or Misoprostol for cervical ripening by studying the effect on newborns
|
From birth until two weeks after birth
|
Percentage of newborns with antibiotic use within 14 days after study intervention
Time Frame: From birth until two weeks after birth
|
This is to measure the safety of either Dilapan or Misoprostol for cervical ripening by studying the effect on newborns
|
From birth until two weeks after birth
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Rachana Gavara, MD, rg2460@cumc.columbia.edu
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AAAR8566
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Labor Onset and Length Abnormalities
-
University of TennesseeRecruitingLabor Onset and Length Abnormalities | Labor Long | Prolonged Labor | Labor; PoorUnited States
-
Ain Shams UniversityCompletedLabor Onset and Length AbnormalitiesEgypt
-
Dilafor ABCompletedLabor Onset and Length AbnormalitiesFinland, Sweden
-
University of California, San FranciscoWithdrawnLabor Onset and Length AbnormalitiesUnited States
-
Stanford UniversityTerminated
-
Wolfson Medical CenterUnknownLabor Onset and Length Abnormalities
-
Universidad Nacional Autonoma de HondurasRecruitingLabor Onset and Length Abnormalities | First BirthHonduras
-
Centro Hospitalar Lisboa NorteRecruitingLabor; Forced or Induced, Affecting Fetus or Newborn | Labor Onset and Length AbnormalitiesPortugal
-
mohamed abosenaAin Shams UniversityCompletedLabor Onset and Length AbnormalitiesEgypt
-
University of ChicagoTerminatedObesity | Labor Onset and Length AbnormalitiesUnited States
Clinical Trials on Dilapan
-
The University of Texas Medical Branch, GalvestonMedicem International CR s.r.o.CompletedLabor, Induced | Cervix Uteri-DiseasesUnited States
-
Albany Medical CollegeTerminatedInduction of Labor Affected Fetus / NewbornUnited States
-
Medicem Technology s.r.o.The University of Texas Medical Branch, GalvestonEnrolling by invitationOligohydramnios | Fetal Growth Retardation | Gestational Diabetes | Post Term Pregnancy | Premature Rupture of Membrane | High Blood Pressure in PregnancyUnited States
-
Medicem International CR s.r.o.CompletedLabor; Forced or Induced, Affecting Fetus or Newborn | Labour Onset and Length AbnormalitiesUnited States, Germany, Czechia, India, Russian Federation, Slovakia, United Kingdom
-
Medicem International CR s.r.o.CompletedAbortion, Induced
-
Planned Parenthood of Greater New YorkSociety of Family PlanningCompletedSecond Trimester AbortionUnited States
-
University of California, San FranciscoCompleted
-
Stanford UniversityCompletedAbortion, Second TrimesterUnited States
-
Medicem International CR s.r.o.Completed
-
Boston UniversityTerminatedAbortion, InducedUnited States